These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 1471601)

  • 1. Thrombolytic, antiplatelet, and antithrombotic agents.
    Grines CL
    Am J Cardiol; 1992 Dec; 70(21):18I-26I. PubMed ID: 1471601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators.
    O'Connor CM; Meese RB; McNulty S; Lucas KD; Carney RJ; LeBoeuf RM; Maddox W; Bethea CF; Shadoff N; Trahey TF; Heinsimer JA; Burks JM; O'Donnell G; Krucoff MW; Califf RM
    Am J Cardiol; 1996 Apr; 77(10):791-7. PubMed ID: 8623729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical therapy of acute myocardial infarction: Part I. Role of thrombolytic and antithrombotic therapy.
    Jafri SM; Walters BL; Borzak S
    J Intensive Care Med; 1995; 10(2):54-63. PubMed ID: 10172420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
    Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
    J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reocclusion three months after successful thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activating complex.
    Takens BH; Brügemann J; van der Meer J; den Heijer P; Lie KI
    Am J Cardiol; 1990 Jun; 65(22):1422-4. PubMed ID: 2191581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.
    Lancet; 1992 Mar; 339(8796):753-70. PubMed ID: 1347801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC).
    Johnson ES; Cregeen RJ
    Drugs; 1987; 33 Suppl 3():298-311. PubMed ID: 3315612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reperfusion, patency and reocclusion with anistreplase (APSAC) in acute myocardial infarction.
    Anderson JL
    Am J Cardiol; 1989 Jul; 64(2):12A-17A; discussion 24A-26A. PubMed ID: 2662737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS).
    Neuhaus KL; von Essen R; Tebbe U; Vogt A; Roth M; Riess M; Niederer W; Forycki F; Wirtzfeld A; Maeurer W
    J Am Coll Cardiol; 1992 Apr; 19(5):885-91. PubMed ID: 1552106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Thrombolytic drugs in acute myocardial infarct].
    Ambrosioni E; Degli Esposti D
    Cardiologia; 1991 Dec; 36(12 Suppl 1):395-402. PubMed ID: 1841796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous thrombolytic therapy in myocardial infarction: an analytical review.
    Shammas NW; Zeitler R; Fitzpatrick P
    Clin Cardiol; 1993 Apr; 16(4):283-92. PubMed ID: 8458108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombolytic therapy in Europe: current status.
    Vahanian A
    Eur Heart J; 1996 Sep; 17 Suppl E():21-7. PubMed ID: 11824000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent.
    Anderson JL
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):22B-27B. PubMed ID: 3312369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet and antithrombin therapy.
    Fernández-Ortiz A; Jang IK; Fuster V
    Coron Artery Dis; 1994 Apr; 5(4):297-305. PubMed ID: 8044341
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction.
    Bossaert LL
    Drugs; 1987; 33 Suppl 3():287-92. PubMed ID: 3315610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic and thrombolytic therapies for acute myocardial infarction.
    Godfried SL; Gaziano JM; Hennekens CH
    J Cardiovasc Risk; 1996 Oct; 3(5):453-7. PubMed ID: 9048261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.
    Crabbe SJ; Grimm AM; Hopkins LE
    Pharmacotherapy; 1990; 10(2):115-26. PubMed ID: 2140889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1.
    O'Connor CM; Meese R; Carney R; Smith J; Conn E; Burks J; Hartman C; Roark S; Shadoff N; Heard M
    J Am Coll Cardiol; 1994 Jan; 23(1):11-8. PubMed ID: 8277068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis.
    Barbagelata NA; Granger CB; Oqueli E; Suárez LD; Borruel M; Topol EJ; Califf RM
    Am Heart J; 1997 Mar; 133(3):273-82. PubMed ID: 9060794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.